StockNews.AI
IONS
StockNews.AI
34 days

Ionis to hold second quarter 2025 financial results webcast

1. Ionis will webcast Q2 2025 results on July 30 at 11:30 AM ET. 2. The company has six marketed medicines and a strong development pipeline. 3. Focus areas include neurology, cardiology, and high patient need therapies. 4. Ionis is a pioneer in RNA-targeted medicines and gene editing. 5. The webcast details likely to reflect progress in key programs.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results can boost investor confidence, following historical examples where similar announcements positively affected stock prices.

How important is it?

Positive financial outlooks and advancements in pipeline can attract investors, showing relevance to IONS’s market performance.

Why Short Term?

The webcast will deliver immediate insights, impacting IONS’s stock in the near term based on investor reactions.

Related Companies

BIIBAVTXSRPT
-Webcast scheduled for Wednesday, July 30 at 11:30 a.m. Eastern Time CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 30th at 11:30 a.m. Eastern Time to discuss its second quarter 2025 financial results and progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. More News From Ionis Pharmaceuticals, Inc.

Related News